Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Arrowhead Pharmaceuticals Inc patents


Recent patent applications related to Arrowhead Pharmaceuticals Inc. Arrowhead Pharmaceuticals Inc is listed as an Agent/Assignee. Note: Arrowhead Pharmaceuticals Inc may have other listings under different names/spellings. We're not affiliated with Arrowhead Pharmaceuticals Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "A" | Arrowhead Pharmaceuticals Inc-related inventors


Compositions and methods for inhibiting gene expression of hif2alpha

Rna interference (rnai) triggers and rnai trigger conjugates for inhibiting the expression of hif2α (epas1) gene are described. Pharmaceutical compositions comprising one or more hif2α rnai triggers optionally with one or more additional therapeutics are also described. ... Arrowhead Pharmaceuticals Inc

Compositions and methods for inhibiting expression of rrm2 genes

The invention relates to a double-stranded ribonucleic acid (dsrna) for inhibiting the expression of a rrm2 gene. The invention also relates to a pharmaceutical composition comprising the dsrna or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a rrm2 gene using said pharmaceutical composition; and methods for inhibiting the expression of rrm2 in a cell.. ... Arrowhead Pharmaceuticals Inc

Compositions and methods for inhibiting gene expression of lpa

Rna interference (rnai) agents and rnai agent conjugates for inhibiting the expression of the lpa (apo(a)) gene are described. Pharmaceutical compositions comprising one or more lpa rnai agents optionally with one or more additional therapeutics are also described. ... Arrowhead Pharmaceuticals Inc

Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use

Rnai agents for inhibiting the expression of the alpha-1 antitrypsin (aat) gene, compositions including aat rnai agents, and methods of use are described. Also disclosed are pharmaceutical compositions including one or more aat rnai agents together with one or more excipients capable of delivering the rnai agent(s) to a liver cell in vivo. ... Arrowhead Pharmaceuticals Inc

Organic compositions to treat kras-related diseases

The present disclosure relates to rnai agents useful in methods of treating kras-related diseases such as a proliferative disease, including without limitation a solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and/or metastatic colorectal cancer, colon cancer, lung, non-small cell lung cancer and lung adenocarcinoma, acute myelogenous lung, bladder, brain, breast, cervical, endometrial, gastric, head and neck, kidney, leukemia, myelodysplastic syndrome, myeloid leukemia, liver, melanoma, ovarian, pancreatic, prostate, testicular, thyroid cancers, and cardio-facio-cutaneous (cfc) syndrome and noonan syndrome, and similar and related diseases, using a therapeutically effective amount of a rnai agent to kras.. . ... Arrowhead Pharmaceuticals Inc

Rnai inhibition of alpha-enac expression

The invention relates to compositions and methods for modulating the expression of alpha-enac, and more particularly to the downregulation of alpha-enac expression by chemically modified oligonucleotides.. . ... Arrowhead Pharmaceuticals Inc

Organic compositions to treat epas1 - related diseases

The present disclosure relates to methods of treating epas1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, rheumatoid arthritis, using a therapeutically effective amount of a rnai agent to epas1.. . ... Arrowhead Pharmaceuticals Inc

Targeting ligands

Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds that are useful in directing the compounds to the in vivo target. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as rnai agents, to liver cells to modulate gene expression. ... Arrowhead Pharmaceuticals Inc

Compositions and methods for inhibiting gene expression of factor xii

Rna interference (rnai) triggers for inhibiting the expression of factor xii (f12) gene through the mechanism of rna interference are described. Pharmaceutical compositions comprising one or more f12 rnai triggers together with one or more excipients capable of delivering the rnai trigger(s) to a liver cell in vivo are also described. ... Arrowhead Pharmaceuticals Inc

Disulfide-containing alkyne linking agents

Described are improved disulfide-containing alkyne linking agents having have branched disulfides. The improved linking agents exhibit improved stability. ... Arrowhead Pharmaceuticals Inc

Organic compositions to treat beta-enac-related diseases

The present disclosure relates to rnai agents useful in methods of treating beta-enac-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (pha1), liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a rnai agent to beta-enac.. . ... Arrowhead Pharmaceuticals Inc

Targeting ligands for therapeutic compounds

Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds, that are useful in directing the compounds to the target in vivo. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as rnai agents, to liver cells to modulate gene expression. ... Arrowhead Pharmaceuticals Inc

Dsrna for treating viral infection

The invention relates to double-stranded ribonucleic acids (dsrnas) targeting gene expression of phosphatidylinositol 4-kinase (pi4k), in particular human phosphatidylinositol 4-kinase, catalytic, beta polypeptide (pik4cb) or human phosphatidylinositol 4-kinase, catalytic, alpha polypeptide (pik4ca), and their use for treating infection by positive stranded rna viruses such as hepatitis c virus (hcv). Each dsrna comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the pik4cb or pik4ca target mrna. ... Arrowhead Pharmaceuticals Inc

Rnai-mediated inhibition of hif1a for treatment of ocular angiogenesis

Rna interference is provided for inhibition of hif1a mrna expression for treating patients with ocular angiogenesis, particularly for treating retinal edema, diabetic retinopathy, sequela associated with retinal ischemia, posterior segment neovascularization (psnv), and neovascular glaucoma, and for treating patients at risk of developing such conditions.. . ... Arrowhead Pharmaceuticals Inc

05/18/17 / #20170137827

Compositions and methods for inhibiting expression of rrm2 genes

The invention relates to a double-stranded ribonucleic acid (dsrna) for inhibiting the expression of a rrm2 gene. The invention also relates to a pharmaceutical composition comprising the dsrna or nucleic acid molecules or vectors encoding the same together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of a rrm2 gene using said pharmaceutical composition; and methods for inhibiting the expression of rrm2 in a cell.. ... Arrowhead Pharmaceuticals Inc

05/18/17 / #20170137814

Organic compositions to treat apoc3-related diseases

The present disclosure relates to compositions and methods for treating apoc3-related diseases such as: hypertriglyceridemia (e.g., type v hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a rnai agent to apoc3.. . ... Arrowhead Pharmaceuticals Inc

04/06/17 / #20170096665

Compositions and methods for inhibiting gene expression of lpa

Rna interference (rnai) agents and rnai agent conjugates for inhibiting the expression of the lpa (apo(a)) gene are described. Pharmaceutical compositions comprising one or more lpa rnai agents optionally with one or more additional therapeutics are also described. ... Arrowhead Pharmaceuticals Inc

03/16/17 / #20170073681

Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma

Rna interference is provided for inhibition of frizzled related protein-1 mrna expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.. . ... Arrowhead Pharmaceuticals Inc

03/16/17 / #20170073678

Organic compositions to treat hsf1-related diseases

The present disclosure relates to methods of treating heat shock factor 1 (hsf1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a rnai agent to hsf.. . ... Arrowhead Pharmaceuticals Inc

03/02/17 / #20170056507

Low density lipoprotein receptor-mediated sirna delivery

The invention provides interfering rna molecule-ligand conjugates useful as a delivery system for delivering interfering rna molecules to a cell in vitro or in vivo. The conjugates comprise a ligand that can bind to a low density lipoprotein receptor (ldlr) or ldlr family member. ... Arrowhead Pharmaceuticals Inc

03/02/17 / #20170056472

Peptide-based in vivo sirna delivery system

The present invention is directed compositions for targeted delivery of rna interference (rnai) polynucleotides to hepatocytes in vivo. Targeted rnai polynucleotides are administered together with co-targeted melittin delivery peptides. ... Arrowhead Pharmaceuticals Inc

02/23/17 / #20170051291

Rnai-mediated inhibition of phosphodiesterase type 4 for treatment of camp-related ocular disorders

Rna interference is provided for inhibition of phosphodiesterase type 4 mrna expression for treating patients with a camp-related ocular disorder. Phosphodiesterase type 4 mrna targets include mrna for 4a, 4b, 4c, and 4d phosphodiesterase isoforms.. ... Arrowhead Pharmaceuticals Inc

02/09/17 / #20170035796

Rnai therapy for hepatitis b virus infection

Described are compositions and methods for inhibition of hepatitis b virus gene expression. Rna interference (rnai) triggers and rnai trigger conjugates for inhibiting the expression of hepatitis b virus gene are described. ... Arrowhead Pharmaceuticals Inc

01/26/17 / #20170022497

Polyconjugates for delivery of rnai triggers to tumor cells in vivo

The present invention is directed compositions for delivery of rna interference (rnai) triggers to integrin positive tumor cells in vivo. The compositions comprise rgd ligand-targeted amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. ... Arrowhead Pharmaceuticals Inc

01/12/17 / #20170009235

Rnai-mediated inhibition of connexin 43 for treatment of iop-related conditions

Rna interference is provided for inhibition of connexin 43 (cx43) in intraocular pressure-related conditions, including ocular hypertension and glaucoma such as normal tension glaucoma and open angle glaucoma.. . ... Arrowhead Pharmaceuticals Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Arrowhead Pharmaceuticals Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Arrowhead Pharmaceuticals Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###